AARD Aardvark Therapeutics, Inc.

company

SEC Filings & Insider Trading Activity 2026

Risk Factors

• • New risk: Material weakness in internal control over financial reporting identified, may affect accurate or timely financial reporting and investor confidence
• • Material update: Net loss increased from $11.8M to $40.0M for nine months ended Sept 30, driven by higher R&D and G&A expenses

What are the latest AARD SEC filings in 2026?

Aardvark Therapeutics, Inc. (AARD) has filed a 10-K annual report on March 23, 2026, a 10-Q quarterly report on November 13, 2025, an 8-K current report on March 24, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did AARD file its most recent 10-K annual report?

Aardvark Therapeutics, Inc. (AARD) filed its most recent 10-K annual report on March 23, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view AARD 10-Q quarterly reports?

Aardvark Therapeutics, Inc. (AARD)'s most recent 10-Q quarterly report was filed on November 13, 2025. SignalX displays every AARD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has AARD filed recently?

Aardvark Therapeutics, Inc. (AARD)'s most recent 8-K was filed on March 24, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find AARD insider trading activity (Form 4)?

SignalX aggregates every AARD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does AARD file with the SEC?

Aardvark Therapeutics, Inc. (AARD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new AARD filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Aardvark Therapeutics, Inc. (AARD).

What is AARD's SEC CIK number?

Aardvark Therapeutics, Inc. (AARD)'s SEC CIK (Central Index Key) number is 1774857. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1774857 to look up all AARD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find AARD return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Aardvark Therapeutics, Inc. (AARD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.